Research programme: SB 9000 - Spring Bank Pharmaceuticals

Drug Profile

Research programme: SB 9000 - Spring Bank Pharmaceuticals

Alternative Names: MBI 1313; MX 1313; ORI 7246; SB 9000; SB 9001; SB 9002 1

Latest Information Update: 29 May 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MIGENIX
  • Developer Spring Bank Pharmaceuticals
  • Class Nucleotides; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 29 May 2013 Discontinued - Preclinical for Hepatitis B in USA (PO)
  • 19 Aug 2011 BioWest Therapeutics is now called Carrus Capital Corporation
  • 08 Apr 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top